Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation

Respiratory Medicine

Volumn 100, Issue 7, 2006, Pages 1277-1281

  Santus, P ^a   Centanni, S ^a   Verga, M ^a   Di Marco, F ^a   Matera, M G ^b   Cazzola, M ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Budesonide formoterol combination; COPD; Inspiratory capacity; Lung hyperinflation; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; PLACEBO; TIOTROPIUM BROMIDE;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HUMAN; HYPERINFLATION; INHALER; INSPIRATORY CAPACITY; MALE; MEDICAL DOCUMENTATION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; REST; SCREENING TEST; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 33646919800     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.10.008     Document Type: Article

References (15)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2003 [accessed April 28, 2005]. Available at:
2. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
3. Boni E., Corda L., Franchini D., Chiroli P., Damiani G.P., Pini L., et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 57 (2002) 528-532
4. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
5. Speizer F., and Comstock G. Recommended respiratory disease questionnaires for use with adults and children in epidemiological research. Epidemiology Standardization Project. Am Rev Respir Crit Care Med 118 (1978) 7-53
6. Coates A.L., Peslin R., Rodenstein D., and Stocks J. Measurement of lung volumes by plethysmography. Eur Respir J 10 (1997) 1415-1427
7. Cotes JE. Lung function. 4th ed. Oxford, UK: Blackwell Scientific Publications; 1979. p. 239-49.
8. Di Marco F., Milic-Emili J., Boveri B., Carlucci P., Santus P., Casanova F., et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21 (2003) 86-94
9. Tantucci C., Duguet A., Similowski T., et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 12 (1998) 799-804
10. O'Donnell D.E., Bain D.J., and Webb K.A. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 155 (1997) 530-535
11. van Noord J.A., Smeets J.J., Custers F.L., Korducki L., and Cornelissen P.J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 639-644
12. Cazzola M., Santus P., Di Marco F., Carlucci P., Mondoni M., Matera M.G., et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 17 (2004) 121-125
13. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
14. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
15. Calverley P.M., and Koulouris N.G. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 25 (2005) 186-199